Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ('Silo' or the 'Company'), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.' The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.
The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in November 2022.
'Strategic IP and patent expansion is key to advancing our lead asset SPC-15 to clinical trials and creating value for our full pipeline of novel assets,' said Eric Weisblum, CEO of Silo. 'This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15.'
Silo announced the USPTO's Notice of Allowance for the new patent in January 2025.
About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words 'could', 'believe', 'anticipate', 'intend', 'estimate', 'expect', 'may', 'continue', 'predict', 'potential', and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ('Silo' or 'the Company') to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact800-705-0120 investors@silopharma.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 minutes ago
- Business Upturn
Ericsson bags multi-year NOC Managed Services contract with Bharti Airtel
Ericsson (NASDAQ: ERIC) has been awarded a significant multi-year Network Operations Center (NOC) Managed Services contract by Bharti Airtel, reinforcing the strong and enduring partnership between the two telecom giants. This strategic collaboration highlights Ericsson's leadership in managed services and its commitment to delivering superior network performance and value to Airtel's customers. Under this new agreement, Ericsson will deploy its advanced intent-based operations through a centralized NOC to efficiently manage Bharti Airtel's diverse network services. These include 4G, 5G Non-Standalone (NSA), 5G Standalone (SA), Fixed Wireless Access (FWA), Private Networks, and Network Slicing. The move aims to enhance network reliability, scalability, and innovation across Airtel's pan-India footprint. Ericsson's state-of-the-art NOC will play a crucial role in managing and scaling Airtel's expansive network infrastructure, especially focusing on expanding Fixed Wireless Access and Network Slicing capabilities throughout the country. This will empower Airtel to offer improved connectivity solutions and cater to evolving customer demands in the 5G era. Randeep Sekhon, CTO of Bharti Airtel, stated, 'We are excited to enhance our strong collaboration with Ericsson as we pursue our goal of creating a future-ready network that delivers an exceptional experience for our customers. We believe that these innovative technologies will empower us to meet the growing data demands of consumers in a digitally connected India.' With a partnership spanning over 25 years, Ericsson and Bharti Airtel have collaborated across multiple generations of mobile communication technologies. This latest contract follows Airtel's recent collaboration with Ericsson on 5G Core technology, further driving the evolution of India's 5G ecosystem. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
13 minutes ago
- Yahoo
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no. 18/351,291 ('291) includes valuable composition-of-matter claims broadly covering therapeutically active ADCs - not limited to individual diseases or therapeutic targets - as well as claims covering the use of ADCs for treating or diagnosing diseases such as cancer. Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Upon grant, the '291 patent application will provide the Company with potential market exclusivity until 2043 for its proprietary second-generation Accum®-based ADCs, which include antibodies conjugated to innovative new constructs featuring a bile acid conjugated to a nuclear localization signal (NLS) derived from the ribosomal protein eS17 (RPS17). This milestone builds on Defence's established patent portfolio for its foundational Accum® technology, which includes granted patents in the United States (US 11,352,437), Japan (JP 7,126,956), Australia (AU 2017233725), and Israel (IL 261765), with applications currently pending in Canada and Europe. "Second-generation Accum®-based ADCs represent a significant advancement in both oncotherapy and targeted drug delivery," said Sébastien Plouffe, CEO and Founder of Defence Therapeutics. "This recent allowance underscores the innovation and versatility embedded in our ADC platform technology and reflects our commitment to developing novel, effective cancer treatments that push the boundaries of current ADC technologies." This newly allowed U.S. patent application is poised to become the eighth granted U.S. patent in Defence's expanding portfolio, which now comprises seven published patent families. About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information:Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
GitLab (GTLB) Reports Q1: Everything You Need To Know Ahead Of Earnings
Software development tools maker GitLab (NASDAQ:GTLB) will be reporting earnings tomorrow after the bell. Here's what you need to know. GitLab beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $211.4 million, up 29.1% year on year. It was a slower quarter for the company, with full-year EPS guidance missing analysts' expectations significantly and EPS guidance for next quarter missing analysts' expectations significantly. Is GitLab a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting GitLab's revenue to grow 25.9% year on year to $213 million, slowing from the 33.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.15 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GitLab has missed Wall Street's revenue estimates twice over the last two years. Looking at GitLab's peers in the software development segment, some have already reported their Q1 results, giving us a hint as to what we can expect. JFrog delivered year-on-year revenue growth of 22%, beating analysts' expectations by 4.4%, and Fastly reported revenues up 8.2%, topping estimates by 4.8%. JFrog traded up 10.9% following the results while Fastly was also up 26.8%. Read our full analysis of JFrog's results here and Fastly's results here. There has been positive sentiment among investors in the software development segment, with share prices up 2.6% on average over the last month. GitLab is down 5.4% during the same time and is heading into earnings with an average analyst price target of $70.36 (compared to the current share price of $49.27). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
